Table 2.
Study calendar
| At registration | 3 months after diagnosis | 6 months after diagnosis | 12 months after diagnosis | |
| Participant background | ||||
| Lifestyle and preference history | 〇 | |||
| Medical history: date of diagnosis, comorbidities, allergies, medications, pregnancy status and route of infection | 〇 | |||
| COVID-19 severity | 〇 | |||
| Physical findings | ||||
| Vital signs | 〇 | |||
| Height and weight | 〇 | |||
| Clinical symptoms* | 〇 | 〇 | 〇 | 〇 |
| Clinical laboratory data | ||||
| Blood test findings† | 〇 | |||
| ECG | 〇 | |||
| Radiological examination | ||||
| Chest radiography | 〇 | |||
| Chest CT scan | 〇 | |||
| Clinical course | 〇 | |||
| Treatment progress and outcomes‡ | 〇 | |||
| Rehabilitation survey | 〇 | 〇 | 〇 | 〇 |
| e-PRO or p-PRO | ||||
| SF-8 Standard Ver. | 〇 | 〇 | 〇 | |
| EQ-5D-5L | 〇 | 〇 | 〇 | |
| HADS | 〇 | 〇 | 〇 | |
| The Pittsburgh Sleep Quality Index | 〇 | 〇 | 〇 | |
| WHO Health and Work Performance Questionnaire (short form) Japanese edition | 〇 | 〇 | 〇 | |
| Fear of Coronavirus-19 Scale, | 〇 | 〇 | 〇 | |
| Modified Medical Research Council Dyspnea Scale | 〇 | 〇 | 〇 | |
| Investigation of sequelae and symptoms other than those covered in the above assessments | 〇 | 〇 | 〇 | |
| Questionnaire about economic status | 〇 | |||
*Fever, cough, sputum, sore throat, nasal congestion, dyspnoea, diarrhoea, vomiting, fatigue, olfactory disturbances, taste disorders, etc.
†Red cell count, white cell counts, haemoglobin level, hematocrit, platelet count, total protein, albumin, total bilirubin, AST, ALT, LDH, ALP, BUN, creatinine, Na, K, Cl, Ca, IP, blood sugar, HbA1c, total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, ferritin, KL-6, and BNP levels, urinary pneumococcal antigen, urinary Legionella antigen, PCT, etc.
‡Use of oxygen and ventilators, antibiotics and antivirals, steroids, treatment effects, date of diagnosis, date of admission and discharge, etc.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; e-PRO, electronic patient-reported outcome; EQ-5D-5L, Euro Quality of Life 5 Dimensions 5 Level; HADS, Hospital Anxiety and Depression Scale; HbA1c, Hemoglobin A1c; HDL, high-density lipoprotein cholesterol; IP, inorganic phosphorus; LDH, lactate dehydrogenase; LDL, low-density lipoprotein cholesterol; p-PRO, paper patient-reported outcome; SF-8, Short Form-8.